Login to Your Account

Financings Roundup

To 'Infinity' and Beyond: $150M to Propel PI3K Inhibitor IPI-145

By Marie Powers
Staff Writer

Friday, December 14, 2012
Four months after raising $76.85 million in an underwritten public offering, Infinity Pharmaceuticals Inc. went back for a heaping plate of seconds, seeking to raise $150 million by pricing an offering of 5.7 million shares of common stock at $26.33 apiece.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription